Reducing Adult Smoking: FDA Needs to Lead the Charge

Nov.28.2022
Reducing Adult Smoking: FDA Needs to Lead the Charge
US teen e-cigarette use declines, however, adult smoking still needs to see progress in reducing numbers.

Author Background: Dr. Matthew Holman is the Vice President in charge of regulatory strategy for PMI in the United States. Prior to joining Philip Morris in September, Holman served as the Director of the Office of Science at the FDA's Center for Tobacco Products.


Source: Duluth News Tribune, image provided by Matthew Holman.


The latest data from the National Youth Tobacco Survey tells a story that you may not have heard before. The U.S. Food and Drug Administration and Centers for Disease Control and Prevention recently released the results of the 2022 survey, which showed a decrease in underage e-cigarette use to levels below the "epidemic" announced by the FDA in 2018. The data shows a continued reversal of the trend.


According to the same data, the percentage of teenagers smoking combustible cigarettes is at its lowest historical level of 1.6%. In fact, over the past few years, there has been a significant decrease in the use of all tobacco products among adolescents. Many stakeholders, including myself, have tirelessly worked towards reducing underage usage and have achieved success.


However, according to data from the American Cancer Society, the decrease in the number of adult smokers has not matched this progress, with 34 million smokers currently in the United States.


The FDA could do more to help Americans quit smoking and should engage in conversations with smokers again, just like it did before releasing the 2018 Tobacco Survey results.


Smoking among adults has also decreased, although not significantly, much like among teenagers. According to public health data, smoking remains the largest single preventable cause of death in the United States. Therefore, while acknowledging the significant progress made in recent years in reducing tobacco use among youths is important, it is equally important to recognize that too many Americans still smoke.


As a senior professional at the FDA for 20 years and recently appointed as the top scientist for the agency's Center for Tobacco Products, I am aware that it is home to talented scientists who want to do more to help smokers make better choices than continuing to smoke - while also preventing underage nicotine use.


So, what can be done to speed up the reduction of adult smoking in the United States? The US public health agencies need to adopt a more balanced approach in promoting tobacco and nicotine products, which is an urgently needed and important strategic move.


The FDA has invested a significant amount of funds in launching multiple multimedia campaigns aimed at reducing underage electronic cigarette use among adolescents and parents. These efforts should continue. However, what is completely missing is similar investment in communicating with adult smokers. The FDA must engage smokers in a consistent, transparent, and meaningful way to help them quit smoking altogether or encourage those who don't quit to switch to innovative smoke-free products. The FDA acknowledges that such products are a better alternative to continuing smoking. Let's make sure adult smokers know this.


The message that all Americans need to hear from health experts is simple: if you don't currently use tobacco products, don't start. If you smoke, quitting is the best option. If you don't quit, switch to smoke-free alternatives. This message is scientifically supported, and the FDA's authorization of nicotine products confirms this. For adult smokers who completely switch to nicotine products, the chance of exposure to harmful chemicals in smoke is significantly reduced, and for certain products, the risk of lung cancer and other smoking-related diseases may be decreased.


Today, smokers are not receiving this crucial message, and that needs to change. Otherwise, nearly 500,000 Americans will continue to die unnecessarily every year. Health experts have a responsibility to proactively share information about better choices with adult smokers, while also continuing to prevent underage tobacco use.


When I was working at the FDA, Commissioner Scott Gottlieb announced a comprehensive plan aimed at getting smokers to switch from traditional combustible cigarettes to less harmful tobacco products or to quit tobacco altogether. The plan was unveiled over five years ago, but until now, the FDA's efforts have primarily focused on preventing underage use. It is now time to take action to assist adult smokers in making better choices.


I hope that my former colleagues at the FDA, who are all exceptional public health scientists, will take necessary action to accelerate the transition towards a healthier America by keeping smokers away from cigarettes.


Statement:


This article is sourced from compiled third-party information and is intended solely for industry exchange and learning.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the accuracy of the content. The translation of this article is solely intended for industry communication and research.


Due to limitations in the translator's skills, the translated article may not accurately reflect the original text. Please consider the original text as the primary source.


2FIRSTS is fully aligned with the position and stance of the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related issues.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BAT Japan opens Glo flagship store in Tokyo's Ginza district, offering glo devices and tobacco sticks,
BAT Japan opens Glo flagship store in Tokyo's Ginza district, offering glo devices and tobacco sticks,
BAT Japan's flagship store in Tokyo's Ginza district opens, offering glo products, personalization services, and a VIP lounge.
Oct.20 by 2FIRSTS.ai
JT Q3 2025: Revenue +18%, Profit +30%; RRP Volume +40%; Guidance Up
JT Q3 2025: Revenue +18%, Profit +30%; RRP Volume +40%; Guidance Up
Japan Tobacco (JT) delivered a strong Q3 2025. Revenue rose 18.3% year over year to ¥947.2 billion, with adjusted operating profit up 27.8% to ¥279.0 billion (+20.8% at constant currency) and net profit up 29.7% to ¥176.7 billion. Growth was led by reduced-risk products (RRP): total RRP volume climbed 40%, with heated tobacco (HTS) up 53%. In Japan, the launches of Ploom AURA and EVO pods pushed HTS category share to 15.5%, while the Ploom user base has nearly doubled versus two years ago.
Oct.30 by 2FIRSTS.ai
Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved
Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved
Altria’s new nicotine pouch On! PLUS™ is slated to launch in the U.S. on October 14, debuting in North Carolina, Texas, and Florida. The product uses NICOSILK™ technology and will offer multiple nicotine strengths. FDA approval has not yet been granted, but Helix says it is proceeding in line with compliance requirements.
Oct.11 by 2FIRSTS.ai
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.
Oct.21
2Firsts Observation|VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation
2Firsts Observation|VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation
2Firsts observed at Stockholm Arlanda Airport that British American Tobacco’s VELO positions the airport environment as a core marketing scenario, deploying large-format LED displays, a full flavour matrix, and clear nicotine-strength segmentation. The brand also features an instructional “How to Use VELO” section and multi-pack sales strategy, showcasing its systematic merchandising capabilities in the Nordic travel-retail channel.
Nov.19 by 2FIRSTS.ai
Exclusive Interview | What’s Changing in Cigars? A Data Firm’s Perspective on the Industry’s Turning Point
Exclusive Interview | What’s Changing in Cigars? A Data Firm’s Perspective on the Industry’s Turning Point
As regulations tighten, consumer habits evolve, and new nicotine products reshape the market, the cigar industry is undergoing a quiet but profound transformation. In this exclusive interview, 2Firsts speaks with Cigar Sense — a data-driven sensory analysis firm — to explore what’s really changing in cigars, and what it means for manufacturers, retailers, and smokers around the world.
Nov.10